Representatives of 340B covered entities are calling for modifications to the discussion draft of a bill in the House of Representatives intended to address drug shortages, which contains language that would eliminate 340B discounts on generic sterile injectable drugs by several manufacturers with at least one indication for a serious disease or condition.
340B Health, which represents public and private nonprofit hospitals and health systems that participate in the federal 340B Drug